Figure 3
Figure 3. Efficient TCR gene delivery by CD8-LV. Activated human PBMCs were left untransduced (ut) or transduced by CD8-LV or VSV-G-LV harboring either the TCR-T58 (A), or the TCR-D115 transgene (B) at an MOI of 2. Transduced PBMCs were analyzed after 7 days for TCR expression using HLA-A2-Tyr multimer staining. Percentages of CD8+/multimer+ cells are displayed in the upper right gate. (C-D) Purified human CD8+ T cells were activated for 3 days and transduced by CD8-LV or VSV-G-LV at an MOI of 2. Seven days later, percentages of TCR-T58+ (C) or TCR-D115+ cells (D) were determined by flow cytometry. Results are expressed as mean ± SEM (n = 3; *P < .05; ***P < .001).

Efficient TCR gene delivery by CD8-LV. Activated human PBMCs were left untransduced (ut) or transduced by CD8-LV or VSV-G-LV harboring either the TCR-T58 (A), or the TCR-D115 transgene (B) at an MOI of 2. Transduced PBMCs were analyzed after 7 days for TCR expression using HLA-A2-Tyr multimer staining. Percentages of CD8+/multimer+ cells are displayed in the upper right gate. (C-D) Purified human CD8+ T cells were activated for 3 days and transduced by CD8-LV or VSV-G-LV at an MOI of 2. Seven days later, percentages of TCR-T58+ (C) or TCR-D115+ cells (D) were determined by flow cytometry. Results are expressed as mean ± SEM (n = 3; *P < .05; ***P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal